MRK Merck and Co Inc

   By Chelsey Dulaney 
 

Merck & Co. said Monday that its experimental drug regimen to reduce nausea in patients receiving chemotherapy met its primary endpoint goal in a late-stage study.

The phase-three study combined Merck's injectable fosaprepitant dimeglumine, called Emend, with antivomiting medicines.

Merck said the regimen provided greater protection from nausea and vomiting after chemotherapy than other antivomiting medicines in the study. Side effects included fatigue and diarrhea.

Merck said it plans to submit its data to the Food and Drug Administration in the second half of the year.

Write to Chelsey Dulaney at chelsey.dulaney@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires